Dr. Reddy's Laboratories completes Phase 1 study of proposed biosimilar of Tocilizumab

20 Dec 2022 Evaluate

Dr. Reddy's Laboratories has successfully completed the Phase 1 study of its proposed biosimilar of Tocilizumab to be used in the treatment of rheumatoid arthritis in adults. The company's Tocilizumab biosimilar candidate 'DRL_TC' successfully met its primary and secondary endpoints in a Phase 1 study.

This Phase I study used a subcutaneous formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of the company's Tocilizumab biosimilar candidate in comparison to reference products. The successful outcome of this study represents an important milestone in Dr Reddy's commitment to making high-quality biosimilar products more accessible and affordable to healthcare providers and patients around the world. Dr Reddy's is developing the proposed Tocilizumab biosimilar as both subcutaneous and intravenous formulations.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1275.05 -1.95 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×